Puma Biotechnology, founded in 2010, is a development-stage biopharmaceutical company dedicated to creating innovative cancer treatments. The company's core mission is to improve the lives of cancer patients by developing novel therapeutics. Puma focuses on in-licensing drug candidates that have completed initial clinical testing and further advancing their development. Their primary product, Nerlynx (neratinib), is targeted at treating HER2-positive breast cancer, with additional research focusing on other forms of cancer.
Notable individuals affiliated with Puma Biotechnology include Alan H. Auerbach, the founder, who has a significant background in oncology drug development. The company has attracted investments from prominent biotech investors and has achieved key milestones such as FDA approval for Nerlynx. Puma's impact is underscored by its contributions to cancer treatment options, offering hope to patients with limited alternatives.
